Dossier assessment
Venetoclax (chronic lymphocytic leukaemia) - Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Venetoclax (chronic lymphocytic leukaemia) - Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Venetoclax (chronic lymphocytic leukaemia) - Benefit assessment according to §35a Social Code Book V
Dossier assessment
Adult patients with chronic lymphocytic leukaemia who are unsuitable for or have failed treatments with a B-cell receptor pathway inhibitor or chemoimmunotherapy
No comparisons with appropriate comparator therapy presented; added benefit neither proven for patients with 17p deletion or TP53 mutation nor for patients without 17p deletion or TP53 mutation
Project details
- Project no.
- A18-82
- Commission
- Commission awarded on 22.11.2018 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
Connected Projects
-
Dossier assessment
Venetoclax (chronic lymphocytic leukaemia) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Venetoclax (chronic lymphocytic leukaemia) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Venetoclax (chronic lymphocytic leukaemia) – Assessment according to § 35a (para. 1, sentence 10) Social Code Book V
Status: Commission completed
-
Dossier assessment
Venetoclax (previously untreated chronic lymphocytic leukaemia; combination with acalabrutinib with or without obinutuzumab) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Venetoclax (chronic lymphocytic leukaemia) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Venetoclax (acute myeloid leukaemia) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed